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Abstract
Background:  Structure-based drug design (SBDD) can provide valuable guidance to drug discovery programs. Robust
construct design and expression, protein purification and characterization, protein crystallization, and high-resolution diffraction
are all needed for rapid, iterative inhibitor design. We describe here robust methods to support SBDD on an oral anti-cytokine
drug target, human MAPKAP kinase 2 (MK2). Our goal was to obtain useful diffraction data with a large number of chemically
diverse lead compounds. Although MK2 structures and structural methods have been reported previously, reproducibility was
low and improved methods were needed.
Results: Our construct design strategy had four tactics: N- and C-terminal variations; entropy-reducing surface mutations;
activation loop deletions; and pseudoactivation mutations. Generic, high-throughput methods for cloning and expression were
coupled with automated liquid dispensing for the rapid testing of crystallization conditions with minimal sample requirements.
Initial results led to development of a novel, customized robotic crystallization screen that yielded MK2/inhibitor complex
crystals under many conditions in seven crystal forms. In all, 44 MK2 constructs were generated, ~500 crystals were tested for
diffraction, and ~30 structures were determined, delivering high-impact structural data to support our MK2 drug design effort.
Conclusion: Key lessons included setting reasonable criteria for construct performance and prioritization, a willingness to
design and use customized crystallization screens, and, crucially, initiation of high-throughput construct exploration very early
in the drug discovery process.
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Background
Structure-based drug design (SBDD) can be an effective
contributor to the identification and optimization of drug
candidates by providing a structural rationale for the
design of improved compounds. Protein crystallization,
structure determination, and the rapid determination of
multiple protein/ligand complexes can be expensive and
time-consuming. Major variables include protein con-
struct design, mutations, and post-translational modifica-
tions, the nature of protein impurities (chemical or
conformational), the choice of ligands or even proteins
for co-crystallization, and the crystallization conditions
themselves. These variables represent an enormous matrix
of experimental possibilities that is difficult or impossible
to explore systematically. Despite these challenges, the
availability of structural information at the preliminary
stages of a drug discovery program is critical to maximize
impact. Therefore, efficient methods developments, tech-
niques and strategies to deliver structures early in a project
are clearly needed.
MAPKAP kinase 2 (MK2) plays a key role in the produc-
tion of pro-inflammatory cytokines such as TNF-α. MK2 is
activated by the mitogen-activated protein (MAP) kinase
p38 [1-3]. Activated MK2 phosphorylates a number of tar-
get proteins in immune cells resulting in cytokine produc-
tion and cellular proliferation and activation. Mice
lacking MK2 are healthy and fertile, but they fail to
increase production of pro-inflammatory cytokines such
as TNF-α, IL-6, and IFN-γ [4] in response to stimuli such
as lipopolysaccharide. MK2 knockout mice are resistant to
the development of collagen-induced arthritis, a model
for human rheumatoid arthritis [5]. The catalytic activity
of MK2 is required to mount the pro-inflammatory
response [6]. These and related studies have attracted
attention to MK2 as a target for the design of therapeutic
treatments for rheumatoid arthritis and other TNF-α-
driven diseases.
Although the data supporting MK2 as a promising drug
target have been available for nearly ten years, to our
knowledge there are no MK2 inhibitors in clinical devel-
opment. Many companies have initiated MK2 projects,
but little success has been reported. Anecdotally, a com-
mon problem has been that high-throughput screening
for lead MK2 inhibitors has been unproductive. We
believe SBDD targeting MK2 could help address this issue.
Yet, despite several reports of MK2 crystal structures at
moderate (2.7–3.8 Å) resolution [7-10], the routine pro-
duction of well-diffracting MK2 crystals bound to com-
pounds of diverse structure remains difficult. More robust
methods are needed to enable efficient SBDD.
The domain structure of MK2 may contribute to these dif-
ficulties [2]. Its proline-rich N-terminal domain (residues
1–65) is unique, having no counterpart in other MAP
kinases [3]. This domain binds c-ABL Src homology 3
domain in vitro [11]. The sequence of the kinase domain
(66–327) identifies MK2 as a Ser/Thr kinase family mem-
ber. MK2 exhibits low homology to other Ser/Thr kinases,
however, with the exception of the close homologs MK3
and MK4. The regulatory domain at the C-terminus (328–
400) contains an autoinhibitory α-helix [7,8] followed by
nuclear export signal (NES) and nuclear localization sig-
nal (NLS) sequences [2,3,12-15]. The NES and NLS are
essential for MK2 complex formation with p38 and subse-
quent translocation to the nucleus. Deletion of the entire
MK2 regulatory domain results in a marked increase in
catalytic activity [15]. There are three critical phosphoryla-
tion sites on MK2: Thr222, Ser272, and Thr334 [16,17].
Phosphorylation at these residues activates MK2 by caus-
ing a conformational change in the C-terminal regulatory
α-helix: on kinase activation, the helix displaces from the
kinase surface and thereby allows substrates to bind
[7,9,16].
Construct design is known to be a critical factor in produc-
ing large quantities of soluble protein and reproducible
crystals. For example, it can be difficult to predict precisely
domain boundaries and to identify the surface residues of
globular proteins, alteration of which might enhance sol-
ubility or crystallization. Altering or deleting features such
as surface hydrophobicity, post-translational modifica-
tions, side-chain flexibility, secondary structural elements,
or even entire domains can dramatically modulate pro-
tein physical characteristics, especially solubility. Protein
solubility also depends on details such as the expression
vector, host cell, culture conditions, and protein fusion
partner used. To increase crystallization robustness and
improve crystal diffraction, we thought such wide-ranging
approaches needed to be explored with MK2.
Here we report the optimization of several steps in human
MK2 structure determination: rapid and systematic explo-
ration of construct design and expression screening; high-
throughput protein purification; and wide screen crystal-
lization with customized factorial grids. Our methods
expand upon those of Malawski et al. [18], who examined
only N- and C-terminal truncations of the MK2 catalytic
domain. We took advantage of the fact that MK2 is one of
the few kinases that expresses well in Escherichia coli,
which facilitates high-throughput construct design and
production, to explore the effect of not only truncations
but also two kinds of surface mutations and several inter-
nal deletions.
Our strategy had four components: First, the N- and C-ter-
mini of the protein were varied. Second, surface-exposed
lysine and glutamate residues with high conformational
entropy [19] were mutated to drive novel crystallizationBMC Structural Biology 2009, 9:16 http://www.biomedcentral.com/1472-6807/9/16
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contacts and thereby enhance crystallization. Third, inter-
nal flexible regions were deleted, again to foster novel
crystal forms. Fourth, phosphorylation sites [16,17] were
altered to provide homogenous MK2 rather than a heter-
ogeneous mixture of unactivated (no phosphorylation)
and activated (partial or full phosphorylation) forms.
We implemented a high-throughput, parallel approach to
enable construct production, expression, and purification
of all mutants within a short time, nearly all of which
expressed well and were tested in customized, kinase-spe-
cific robotic crystallization screens. The methodological
improvements implemented here enabled the screening
of 44 MK2 constructs, resulting in seven crystal forms, dif-
fraction testing of ~500 crystals, and high-resolution data
collection and structure determination of ~30 MK2/inhib-
itor complexes.
Results and discussion
We initiated MK2 crystallographic studies with a construct
(Table 1) comprising part of the proline-rich domain, the
kinase and C-terminal regulatory domains, and a point
mutation introduced to abolish kinase activity. MK2(36–
401, K93R) disrupts the highly conserved catalytic lysine
residue; the catalytically-inactive K93R mutation was
described previously [6]. We began with an inactive con-
struct because use of inactive kinases proved critical to our
obtaining homogenous protein suitable for crystallogra-
phy on several earlier projects. It quickly became appar-
ent, however, that these MK2 constructs were not suitable
for structural studies, due to both low expression levels
and relative insolubility, likely due in part to the proline-
rich segment. We switched to a construct that had been
used to determine the first reported MK2 crystal structure,
MK2(47–400) [7]. Although protein expression and
behavior improved, suitable crystals were not forthcom-
ing, despite success in another laboratory. We believed
that a new, more robust approach was clearly needed.
Construct Design Strategy
We thus implemented a broad, four-point MK2 construct
design strategy coupled with the high-throughput produc-
tion and testing of multiple crystallographic constructs.
First, we sought to parlay the domain organization of
MK2 into a series of N- and C-terminal truncation
mutants that either incorporated multiple domains of the
intact protein, or defined the kinase domain more pre-
cisely than a single construct would. Our approach was
significantly more extensive than that of Malawski et al.
[18]. Second, we mutated surface-exposed lysine and
glutamate residues to alanine, to reduce the high confor-
mational entropy of these residues [19]. This approach
has been used successfully in a variety of contexts [20].
Third, the flexible internal activation loop of MK2 was
deleted. Fourth, phosphorylation sites were altered to pro-
vide homogenous MK2 rather than a heterogeneous mix-
ture of unactivated (no phosphorylation) and activated
(partial or full phosphorylation) forms. A representative
subset of the constructs we used is shown in Table 1; the
complete list of constructs is also available (see Additional
File 1 Table S7). Figure 1 illustrates the location of all
mutation sites mapped onto the MK2 three-dimensional
structure.
Our initial construct design tactic was alteration of the N-
or C-termini of full-length MK2, thereby either removing
flexible terminal segments that might hinder crystalliza-
tion or simply providing different termini that might ena-
ble different crystal forms (via altered packing, isoelectric
point, hydrophobicity, etc.). This approach has been used
previously by several groups, and limited systematic N-
and C-terminal truncations have been explored [18]; the
construct used most often has been MK2(41–364), a form
of the enzyme noted to be constitutively-active [8]. Given
the poor behavior of the early constructs that included
(part of) the proline-rich N-terminal domain, we deleted
this domain in all subsequent constructs. We explored
several termini: Gln41, His47, and Arg50; and Gln327,
Leu342, Asp345, Thr357, Arg364, Asp366, and His400
(Figure 1). These residues delineate the kinase domain at
the N-terminus, and the kinase domain, the autoinhibi-
tory α-helix, and the NES/NLS at the C-terminus.
Our second tactic addressed the protein physical charac-
teristic of surface entropy. Following Longenecker and
colleagues [19], a series of point mutants was designed to
alter flexible surface lysine and glutamate residues to min-
Table 1: Representative MK2 expression constructs.
Rationale Constructs
N- and C-terminal variations MK2(36–400, K93R)
MK2(41–364)
MK2(47–357)
MK2(47–366)
Entropy-reducing surface mutations MK2(41–364, K64A)
MK2(41–364, K343A, E344A)
MK2(47–366, K84A)
MK2(47–366, E88A, K89A)
Activation loop deletions MK2(41–364, Δ(L220-G238))
MK2(47–366, Δ(L220-G238))
Pseudoactivation mutations MK2(41–364, T222E)
MK2(41–364, T334E)
MK2(41–364, T222E, T334E)
MK2(47–366, T222E)
MK2(47–366, T334E)
MK2(47–366, T222E, T334E)
The complete list of MK2 constructs is available in Additional File 1 
Table S7.BMC Structural Biology 2009, 9:16 http://www.biomedcentral.com/1472-6807/9/16
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imize crystal protein entropy and entropic loss on crystal-
lization. This approach was successfully used with
RhoGD1, for which new crystal forms were identified that
exhibited enhanced diffraction. Several MK2 mutants in
which alanine was substituted for lysine or glutamate are
shown in Table 1 (see also Figure 1 and Additional File 1
Table S7). All mutants were constructed at one time, with-
out iterative improvements.
Our third tactic addressed the internal flexibility of MK2.
In several of the prior MK2 structures, the kinase activa-
tion loop (residues 220–238) engages in significant crys-
tal contacts. We hypothesized that deletion of this long,
flexible loop (Figure 1) might drive formation of alter-
nate, better-diffracting crystal lattices. We thus examined
two activation loop deletions: MK2(41–364, ΔL220-
G238) and MK2(47–366, ΔL220-G238).
Our final tactic sought to reduce the chemical and confor-
mational heterogeneity of MK2. All reported MK2 struc-
tures are of the unphosphorylated enzyme. Previous
studies had shown that mutation of phosphothreonine
residues to glutamate led to constitutive activation of the
kinase [16,17]. We reasoned that by altering the activation
state of the protein, we would not only access a more
homogeneous enzyme but also distinct conformational
states, and hence increase the likelihood of useful crystal
forms. The pseudoactivated mutants were based on two
truncated constructs, MK2(41–364) and MK2(47–366).
Glutamate mutations T222E and T334E (both singly, and
as the double mutant) replaced the threonines reported to
activate MK2 when phosphorylated. We prioritized muta-
tion of T222 and T334 over S272 because existing data
suggested that the threonine residues were the more sig-
nificant MK2 phosphorylation sites [16]. T334 is shown
in Figure 1; T222 is located within the disordered portion
of the activation loop.
Expression, Purification and Crystallization
The MK2 constructs (Table 1; Additional File 1 Table S7)
were cloned using standard techniques and expressed in
E. coli as glutathione S-transferase (GST) fusion proteins.
The expression plasmids encoded GST followed by
thrombin and tobacco etch virus (TEV) protease cleavage
sites and the desired MK2 sequence. It proved important
to develop a method for rapid generation and screening of
multiple constructs in parallel. After plasmid construction
(PCR, mutagenesis, ligation, etc.) and transformation,
typically in parallel sets of 4–8 constructs, test expression
was carried out on a small scale, to examine both yield
and especially protein solubility. Representative results
are shown in Figure 2 and Table 2. Low temperature
induction (18°C) provided the optimal balance between
expression yield and solubility for most constructs; higher
temperatures increased the proportion of insoluble pro-
tein. One pseudoactivated construct, MK2(47–366,
T222E), exhibited robust expression with both low and
medium temperature induction; typical results are also
MK2 structure and location of mutagenesis sites Figure 1
MK2 structure and location of mutagenesis sites. MK2 
is represented as a ribbon diagram, a composite of Protein 
Data Bank entries 1KWP and 1NXK. The mutagenesis sites 
(see Table 1 and Additional File 1 Table S7) are colored by 
tactic: (1) N-terminal variations, purple/blue/cyan, C-terminal 
variations, yellow/orange/red; (2) entropy-reducing surface 
mutations, light-green; (3) internal deletions, grey-green; and 
(4) pseudoactivation mutations, dark-green. Missing residues 
are represented as dots.
Analysis of MK2(47–366, T222E) expression as a function of  temperature Figure 2
Analysis of MK2(47–366, T222E) expression as a func-
tion of temperature. Total, soluble, and insoluble fractions 
(see Methods) were separated by 4–20% SDS-PAGE; stained 
with Coomassie Blue. Lanes: (1) MW markers; (2–4) control 
(uninduced); (5–7) 18°C; (8–10) 27°C; (11–13) 37°C;. T, 
total; S, soluble; I, insoluble. All samples were taken 5 h after 
induction with IPTG. See also Table 3.BMC Structural Biology 2009, 9:16 http://www.biomedcentral.com/1472-6807/9/16
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shown in Figure 2. This systematic expression/solubility
triage was used for all constructs. Constructs that
expressed at high (soluble) levels were prioritized for
small-scale purification.
Routine procedures (glutathione affinity chromatogra-
phy, TEV protease cleavage, cation exchange and finally
size exclusion chromatography) were used to purify the
MK2 constructs. Initially, limited attempts were made to
purify proteins using parallel 24-well methods (filtration
plates, etc.). But, the rapidity with which conventional
purification could be performed made the use of small-
scale plate methods unnecessary. Yields from the glutath-
ione affinity chromatography capture step were 4–30 mg/
L of culture; the parental constructs MK2(41–364) and
MK2(47–366) had crude yields of 5 mg/L. Final yields for
all constructs were 0.4–12 mg/L. Constructs that gave the
highest yields were progressed first to large-scale purifica-
tion and crystallization trials; only one construct,
MK2(47–366, K56A), produced less than 0.5 mg/L and
therefore was not progressed. Example yields for several
pseudoactivated constructs are shown in Table 3.
MK2(47–366, T222E) was found to be devoid of enzy-
matic activity, in agreement with previous reports that
more than one (pseudo)phosphorylation is required to
activate MK2 [16]. A typical example of the high purity
afforded by our purification scheme is shown in Figure 3
for MK2(47–366, T222E).
Forty-three of forty-four constructs produced crystals
using commercial crystallization screens (Hampton Crys-
tal Screen I/II™ and Wizard Screen I/II™). The most com-
mon crystallization condition was 2 M (NH4)2SO4, 0.2 M
Li2SO4, 0.1 M CAPS, pH 10.5. Crystals were optimized
with an emphasis on finding novel conditions. We created
a customized in-house crystallization grid to optimize co-
crystallization conditions for a variety of MK2/inhibitor
complexes (Table 4; complete crystallization reagent com-
positions are listed in Additional File 1 Table S8). Seven
crystal forms were ultimately identified (Figure 4, Table
5); three of these have been independently identified by
other investigators: Form IV [8-10,21]; Form V [9,22]; and
Form VII [9]. Beyond MK2, we have since used this and
similar grids to crystallize other kinase/inhibitor com-
plexes.
Three pseudoactivated constructs were analyzed for dif-
fraction: MK2(41–364, T222E), MK2(47–366, T222E),
and MK2(47–366, T334E) (Table 3). Although all yielded
moderate amounts of protein and crystals suitable for dif-
Table 2: Solubility assessment for representative MK2 
constructs.
MK2 Construct Solubility
Backbone Mutation(s) 18°C 27°C 37°C
41–364 -- Low Low Low
41–364 K64A Low Low Low
41–364 Δ(L220-G236) High High High
41–364 T222E Low Low Low
41–364 K330A Low Low Low
41–364 T334E Low Low Low
41–364 K343A, K344A, K364A Low Low Low
47–366 -- High High Medium
47–366 K64A High High Medium
47–366 K84A High Med Low
47–366 Δ(L220-G236) High High High
47–366 T222E High High Low
47–366 T222E, T334E Low Low Low
47–366 T334E Low Low Low
Expression tests were conducted at three temperatures for each 
construct. Low (<10%), medium (10–50%) and high (>50%) grades 
were assigned to each construct based on the ratio of soluble/
insoluble MK2 as assessed by SDS-PAGE. An example gel is shown in 
Figure 2.
Representative MK2 purification: MK2(47–366, T222E) Figure 3
Representative MK2 purification: MK2(47–366, 
T222E). Protein fractions were separated by 4–20% SDS-
PAGE; stained with Coomassie Blue. Lanes: (1) MW markers; 
(2) glutathione affinity column flow-thru; (3) glutathione affin-
ity column eluate (40 mM glutathione, pH 8.0); (4) TEV pro-
tease cleavage; GST is present below MK2; (5) MonoS 10/10 
eluate (~200 mM NaCl); (6) Superdex 75 10/60 peak frac-
tion.BMC Structural Biology 2009, 9:16 http://www.biomedcentral.com/1472-6807/9/16
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fraction testing, only one, MK2(47–366, T222E), dif-
fracted well. The detergent Anapoe 80 proved to be
extremely effective with these crystals, improving diffrac-
tion to 2.9-Å resolution (Form IV, Table 6). Crucially, this
crystal form was used to solve our first MK2 structure in
complex with a prototypical inhibitor chosen from our
high-throughput screening lead chemotype. As the project
progressed, however, it was supplanted by other crystal
forms (especially Forms V-VII) that were more amenable
to co-crystallization.
Pseudoactivated MK2 adopts the conformation of inactive 
MK2
The crystal structure of pseudoactivated MK2 in complex
with a micromolar lead compound was determined in
space group F4132 (Table 6). This crystal form was
reported subsequent to our work by other investigators [8-
10]. Superimposition with apo-MK2 (Protein Data Bank
entry 1KWP[7]) illustrates a similar "closed" conforma-
tion Figure 5. One significant difference is observed in the
arrangement of the glycine-rich loop, which assumes a
non-canonical orientation by flipping away from the
active site to form a short helix. This rearrangement
increases the solvent exposure of the ATP binding pocket,
making this crystal form a good candidate for inhibitor
soaking. We successfully soaked an MK2-specific inhibitor
into the ATP binding pocket, leading to our reference crys-
tal structure (Figure 5). Due to the disorder of the activa-
tion loop, we were unable to resolve the T222E
pseudoactivating mutation. Although the mutation was
not directly involved in driving a novel crystal form,
through altered crystal packing or (apparently) a signifi-
cantly altered activation loop conformation, we believe
that the enhanced solubility and stability MK2(47–366,
T222E) facilitated crystallization.
Structural Correlates
For reasons that are still unclear, MK2 has an overwhelm-
ing propensity to make specific, trimer-forming intermo-
lecular contacts as it crystallizes. Some of our mutations
abrogated these contacts; instead of shifting crystalliza-
tion to new conditions and crystal forms, however, those
MK2 constructs simply did not crystallize. Thus, a level of
mutagenesis that would be sufficient for most proteins of
this size was surprisingly less effective with MK2.
What are these trimers? As noted by Hillig et al. [18], two
distinct packing interactions are present in both Form IV
(space group F4132; PDB entry 2JBO[9]) and Form VII
(P212121; PDB entry 2JBP[9]) MK2 crystals (Table 5). The
Type 1 trimer is mediated by a draping of the N-terminus,
beginning around residue 47, over the N-lobe of another
MK2 subunit. Constructs beginning at residues 41 or 47
retain this contact and crystallize; those beginning at resi-
due 50 lose the contact and do not form crystals. The Type
2 trimer is mediated by the C-terminal portion of the acti-
vation loop packing against helices F, G, and H. Con-
structs in which the activation loop was deleted, being
unable to form these contacts, do not crystallize. Notably,
Glu233-Arg313 and Glu238-Arg280 salt bridges mediate
Type 2 contacts. Targeting of these glutamate residues in a
second round of entropy-reduction mutagenesis might
have altered the Type 2 contacts enough to spur formation
of other crystal forms.
MK2 trimer formation is due entirely either to crystallo-
graphic symmetry (Form IV) or to non-crystallographic
symmetry (Form VII). Form IV has one molecule/asym-
metric unit, and the two types of trimers are formed by
adjacent, non-intersecting crystallographic 3-fold symme-
try axes. Conversely, since space group P212121 has no 3-
fold axes, the 12 molecules/asymmetric unit in Form VII
are arranged such that both trimer types are formed by
two non-crystallographic 3-fold axes that nearly intersect
in the center of the 12-subunit, virus-like MK2 shell.
Amazingly, all characterized MK2 crystal forms shown in
Table 5 are composed of Type 1 and/or Type 2 trimers.
Forms V and VI (both P63; e.g., PDB entry 1NXK[8]) have
four molecules/asymmetric unit; three subunits form the
Type 1 non-crystallographic trimer; the fourth, "odd man
out" subunit forms, through crystallographic symmetry,
the Type 2 trimer. And, the tenuous packing in Form III
(P213; four molecules/asymmetric unit, 78% solvent) is
mediated by trimer formation at two adjacent, non-inter-
secting crystallographic 3-fold axes, as in the other cubic
(Form IV) crystal form. Only the first reported MK2 struc-
ture (R3; PDB entry 1KWP; two molecules/asymmetric
unit) breaks the pattern [7]. Uniquely compared to all
other MK2 crystals, the construct used in that study
included the complete MK2 C-terminus. Packing in this
Table 3: Summary of pseudoactivated MK2 construct expression, enzymatic activity, and crystallization.
Construct Yield (mg/L) Enzymatic Activity (cts/nM) Crystallography
Crude Final Without p38 activation With p38 activation Crystals Obtained? Diffraction?
MK2(41–364, T222E) 3.0 1.0 0.30 0.34 Yes No
MK2(47–366, T222E) 6.0 4.0 <0.02 <0.02 Yes Yes
MK2(47–366, T334E) 4.5 2.0 1.5 1.2 Yes NoBMC Structural Biology 2009, 9:16 http://www.biomedcentral.com/1472-6807/9/16
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Seven MK2 crystal forms were identified (Table 5) Figure 4
Seven MK2 crystal forms were identified (Table 5). (a) Form I: MK2(41–364, K343A, K344A, K364A); 2 M (NH4)2SO4, 
35 mM Cymal®-3 (3-cyclohexyl-1-propyl-β-D-maltoside). (b) Form II: MK2(47–366); 2 M (NH4)2SO4, 100 mM HEPES, pH 7.0, 
100 mM Li2SO4. (c) Form III: MK2(47–366); 2 M (NH4)2SO4, 0.1 M Na citrate, pH 5.0, 4% 1,4-butanediol. (d) Form IV: 
MK2(47–366, T222E), 2 M sodium malonate, pH 5.5, 0.01 mM Anapoe 80. (e) Form V: MK2(41–364); 1.5 M Na malonate, pH 
8.0. (f) Form VI: MK2(41–364); 1.8 M Na malonate, pH 8.0. (g) Form VII: MK2(41–364); 1.75 M (NH4)2SO4, 0.1 M Na citrate, 
pH 8.0. Crystals grew to a maximal size of ~0.1–0.2 × 0.1–0.2 × 0.2 mm (Forms V-VII); other crystals were ~0.1 × 0.1 × 0.1 
mm (Forms III & IV) or smaller. See Table 5 for additional details.BMC Structural Biology 2009, 9:16 http://www.biomedcentral.com/1472-6807/9/16
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crystal form is mediated by the Type 1 trimer (crystallo-
graphic 3-fold) and a novel (parallel, crystallographic)
trimeric contact centered at residue 370 that positions the
extended C-terminus (ordered to residue ~385) to pack
against another MK2 subunit.
Although the biological relevance of MK2 trimer forma-
tion is unknown, we note that trimer formation is struc-
turally incompatible with formation of the MK2-p38
complex [23,24]. Thus, MK2 trimer formation may be a
form of self-regulation relevant in vivo.
In summary, much of the mutagenesis work reported here
was, in the end, stymied by the unusually strong proclivity
of MK2 toward trimer formation. Nonetheless, our sys-
tematic approach did indicate that truncations rather than
mutations were more effective for MK2 crystallization.
The exact position of the MK2 N-terminus is more impor-
tant than is the C-terminus, and the activation loop could
not be deleted. Surface arginine and glutamate residues
drive crystallization more strongly than do surface lysine
residues prevent it. The pseudoactivation constructs were
helpful, likely due to slight modulation of protein surface
properties rather than by producing a different protein
conformation. These unusual MK2 properties result in
many closely related (though at first glance apparently dif-
ferent) crystal forms (Table 5). Additional surface mutants
(including untargeted glutamates, and also arginines)
would seem to be required to drive MK2 into truly differ-
ent crystal forms that can be produced under low ionic
strength (e.g., polyethylene glycol) conditions rather than
in high salt.
Conclusion
The systematic methods for the design, production and
evaluation of MK2 protein constructs presented here
allowed us to reproducibly obtain suitable crystals such
that structure-based drug design could proceed. Our
methods are robust and allowed rapid evaluation of about
fifty constructs. This rapidity enabled the scale-up produc-
tion of selected MK2 constructs in multi-milligram quan-
tities proteins for structural studies. Using rational site-
directed mutagenesis and in-house customized crystalli-
zation screens (Table 4), we were able to identify several
novel crystallization conditions. Combined with varia-
tion of other parameters, such as surface side chain
entropy and (pseudo)activation state, these high-through-
put techniques produced five new MK2 crystal forms,
most with improved diffraction characteristics (Table 5).
One such crystal form, grown with a MK2 phosphoryla-
tion-site pseudoactivation mutant, was used to solve our
first MK2/lead inhibitor complex (Figure 5).
Several key lessons were learned from this exercise. First,
setting reasonable criteria for construct performance and
prioritization is essential to identify constructs suitable for
further evaluation and possible scale-up. In the case of
MK2, most constructs gave satisfactory performance in
expression and purification. Choices were necessary, how-
ever; we prioritized higher-yielding, more soluble con-
structs (Table 2) for scale-up and more extensive
crystallization screening. Implicitly, we assumed that con-
structs that expressed or purified poorly were less likely to
crystallize well. Our assumption appears to be supported
by the expression yield, protein melting point, and crystal-
lization data of Malawski et al. [18]. Second, a systematic
crystallization screen (Table 4; see also Additional File 1
Table S8) was required to identify crystallization condi-
tions in a robust manner. Indeed, the interplay between
multiple constructs and multiple, customized crystalliza-
tion solutions likely contributed greatly to our success. We
note that the composition of customized crystallization
screens is protein-specific – for MK2, we used a prepon-
derance of high ionic strength conditions, since repeated
screening with, for example, PEG solutions never pro-
vided crystals. Other proteins will behave differently.
Third, reduction of surface side chain entropy can require
several iterative rounds before productive mutation sites
are identified. In retrospect, more than one round of sur-
face residue mutations in this study, optimally informed
by initial structural information, might have yielded addi-
tional crystal forms (e.g., mutation of Glu233 and Glu238
to disrupt the Type 2 trimer contact). Fourth, high
throughput construct exploration must be initiated early
in a drug discovery program in order to synchronize with
hit-to-lead synthetic chemistry efforts, preferably in con-
cert with initial target selection studies, i.e. before a high-
Table 4: Customized MK2 robotic crystallization screen 
conditions.
Variable Parameters
Buffer Citrate
HEPES
pH 7.0 – 8.5
Precipitant Ammonium Sulfate
Ammonium Malonate
Na Malonate
K Malonate
Na/K Phosphate
Additives DMSO
2-Propanol
PEG 400
PEG 3350
Na Malonate
Na Citrate
The complete screen composition is available in Additional File 1 
Table S8.BMC Structural Biology 2009, 9:16 http://www.biomedcentral.com/1472-6807/9/16
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throughput inhibitor screen is begun. This head start is
especially critical for problematic crystallization targets
like MK2. Applying these lessons learned from our experi-
ence with MK2 has helped us to accelerate many other
structural programs, enabling us to impact lead discovery
programs more rapidly and efficiently.
Methods
Cloning
Most human MK2 http://www.expasy.org/uniprot/
P49137 constructs were engineered as fusion proteins
with  Schistosoma japonicum glutathione  S-transferase
(GST; http://www.expasy.org/uniprot/P08515), using the
pGEX4T-1 vector (GE Healthcare). The sequence used
was: GST-(SDLVPR↑GSENLYFQ↑G)-MK2. The linker
sequence encodes thrombin and tobacco etch virus (TEV)
protease cleavage sites ("↑"). Two protease sites were
included for maximal flexibility in removal of the fusion
tag after purification; we almost exclusively used the TEV
protease site, resulting in an unnatural glycine residue N-
terminal to MK2. A few constructs were also made as His6-
FLAG-TEV-MK2 fusion proteins, using the pET21a+ vector
(Invitrogen). The sequence used was: (MGHHHHHHGS-
GDYKDDDDKDYDIPTTENLYFQ↑G)-MK2. We refer to
these vectors as "pGEX4T-1-GST-Thr-TEV" and "pET21a+-
His6-FLAG-TEV", respectively.
Mutagenic primers were designed according to the Quik-
Change XL Site-Directed Mutagenesis Kit (Stratagene)
Table 5: Seven MK2 crystal forms.
Form Construct(s) Crystallization 
Conditions *
Space Group Unit Cell (a, >b, c, Å) Res. (Å) N †N o t e s
I MK2(41–364) & 
MK2(47–366) surface 
mutants ‡
AS, LS, & NP
pH 5–8
N.D. N.D. >11
N.D.
Rods; high mosaicity
II MK2(41–364) & 
MK2(47–366) surface 
mutants ‡
AS, LS, & NM
pH 5–8
N.D. N.D. >11
N.D.
Plates; high mosaicity
III MK2(47–366) 2 M AS
0.1 M Na citrate
pH 5.0
4% 1,4-butanediol
P213 215 3.4
4
Cubes
IV MK2(47–366, T222E) 2 M NM
pH 5.5
10 μM Anapoe 80
F4132 254 2.9
1
Bipyramids; inhibitor 
soaking req'd
V MK2(41–364) 1.5–1.8 M NM
pH 8.0
P63 158
158
138
2.6–3.3
4
Hex. bullets; co-crystals
VI MK2(41–364) 1.5–1.8 M NM
pH 8.0
P63 144
144
152
2.6–3.3
4
Hex. bullets; co-crystals; 
"collapsed" Form V
VII MK2(41–364) 1.75 M AS
0.1 M Na citrate
pH 8.0
P212121 140
180
215
2.6–3.3
12
Sharp blocks; co-
crystals
* AS – (NH4)2SO4; LS – Li2SO4; NM – sodium malonate; NP – sodium phosphate.
† Resolution of diffraction. N – MK2 molecules/crystallographic asymmetric unit.
‡ Constructs 23, 24, 26, 27, 29, 32, 33, 35, and 36 (Form I), and 9, 24, and 33 (Form II) in Additional File 1 Table S7.
Table 6: Crystallographic statistics for an MK2/lead compound 
inhibitor complex.
Parameter Value
Construct MK2(47–366, T222E)
Crystal form IV
Space group F4132
Resolution (Å) 20.0–2.9
Unit cell length (a; Å) 253.508
Unique reflections 29,178
Rsym 0.069
7 I/σI 8 10.9
Data completeness (%) 99.7
Mean multiplicity 8.2
Rcryst (%) 22.9
Rfree (%) 26.8BMC Structural Biology 2009, 9:16 http://www.biomedcentral.com/1472-6807/9/16
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instructions and were purchased from Invitrogen. Briefly,
primer pairs were made for each mutation. Both primers
in each pair contained the desired mutation and annealed
to the same sequences on opposite strands of the plasmid
template. The desired mutations (nucleotide replace-
ments or deletions), in the middle of each primer, were
flanked by 15–19 bases of wildtype sequence on both
sides. Primer stocks and dilutions were arrayed in 96-well
V-bottom microplates (MJ Research) and stored at -20°C.
Site-directed mutagenesis was performed using the Quik-
Change kit (Stratagene) using the plasmids pGEX4T-1-
GST-Thr-TEV-MK2(47–366) and pGEX4T-1-GST-Thr-
TEV-MK2(41–364) as templates. PCR was performed in
96-well V-bottom microplates using a DNA Engine Dyad
(MJ Research) thermocycler complete with an ALS-1296,
96-well alpha unit (MJ Research). Reaction mixtures were
cycled 18 times according to this schedule: 95°C, 50 s;
60°C, 50 s; 68°C, 14 min. Cycling was preceded by incu-
bation at 95°C (1 min) and followed by incubation at
68°C (7 min).
Transformation of XL-10 Gold Ultracompetent E. coli cells
(Stratagene) was performed in 24-well RB Blocks (Qia-
gen). Thawed cells (45 μL) were mixed on ice with 2 μL of
2-mercaptoethanol in each well. A 5 μL aliquot of each
PCR reaction mix was added to the appropriate well and
the mixture was incubated on ice for 10 min. The blocks
were then heat-shocked by immersing the lower half of
the blocks into a 42°C water bath (30 s), then placing the
block back on ice (2 min). SOC medium (0.5 mL; pre-
heated to 42°C) was then added to each well and the
block was immediately placed in an incubator at 37°C for
1 hr with shaking. A 0.1 mL aliquot of each transforma-
tion was spread onto 100 mm LB agar plates containing
100 μg/mL ampicillin and incubated overnight at 37°C.
Plasmid DNA was prepared using the QIAprep 8 Turbo
Miniprep Kit (Qiagen) in combination with the Qiavac 6S
vacuum manifold (Qiagen) according to manufacturer's
instructions. The DNA was quantitated spectrophotomet-
rically and diluted to 100 μg/mL with water for sequence
analysis. The coding sequence of all constructs was veri-
fied.
Expression
Plasmids encoding the MK2 constructs were transformed
into BL21 (DE3) strain for expression studies. Competent
cells were transformed with 0.5 μL of each plasmid in 24-
well blocks as above (without 2-mercaptoethanol). The
transformation mix (0.1 mL) was spread onto 100 mm LB
agar plates containing 100 μg/mL ampicillin and incu-
bated overnight at 37°C. Starter cultures grown at 37°C
were used to inoculate 2.5 mL of LB medium containing
100 μg/mL ampicillin in 24 deep-well blocks. Once an
OD600 of 0.4–0.6 was reached, the blocks were shifted to
18°C for 1 h and then induced with IPTG (0.4 mM) for 4
h. Cells were harvested by centrifugation, frozen at -80°C.
Large-scale cultures were induced in the same way with
the exception that the flasks were shifted to 4°C for 40
min prior to induction.
Analysis of the soluble and insoluble fractions was per-
formed by SDS-PAGE on 4–20% gels (Invitrogen). Cells
were thawed and resuspended for lysis in Bug Buster HT
(Novagen; 0.25 mL per unit OD600). Bugbuster HT con-
taining 60 kU rLysozyme (Novagen; 0.1 mL) was added to
the cell suspension (0.1 mL). The mixture was incubated
on ice for 15 min before addition of 0.2 mL of Bugbuster
HT containing 20 mM DTT and Complete, EDTA-free Pro-
tease Inhibitor cocktail (Roche; 1 tablet/30 mL Bugbuster
HT). An aliquot of the crude lysate was separated by cen-
trifugation; the supernatant was analyzed as the soluble
fraction. The pellet was resuspended in an equal volume
of BugBuster HT and analyzed as the insoluble fraction.
Proteins were visualized with SimplyBlue stain (Invitro-
gen)
Western blotting was used to confirm protein identity.
Gels were transferred to PVDF membranes using a Protean
Structure of MK2(47–366, T222E) bound to a lead com- pound Figure 5
Structure of MK2(47–366, T222E) bound to a lead 
compound. The micromolar-potency inhibitor was soaked 
into a Form IV crystal. The inhibitor, represented as a tan 
molecular surface, binds deeply in the ATP pocket of 
MK2(47–366, T222E) (rainbow coloring). Apo-MK2 (PDB 
entry 1KWP; light-grey) is shown for comparison.BMC Structural Biology 2009, 9:16 http://www.biomedcentral.com/1472-6807/9/16
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II Mini Trans-Blot apparatus (BioRad). After blocking
membranes with 5% nonfat dry milk in TBS-T buffer (50
mM Tris·HCl, pH 8.0, 150 mM NaCl, 0.1% Tween-20),
the blot was probed with horseradish peroxidase-conju-
gated anti-GST antibody diluted 1:1000 in TBS-T/5% non-
fat milk. Membranes were washed extensively with TBS-T,
and then bound antibodies were visualized using the
SuperSignal West Pico chemiluminescent substrate kit
(Pierce).
Purification
MK2 variants were purified using the following procedure
at 4°C: Cell pellets were thawed and resuspended in lysis
buffer containing 50 mM Tris·HCl, 250 mM NaCl, 10%
glycerol, 1 mM DTT, 1 mM EDTA, pH 7.5. The cell suspen-
sion was sonicated on ice for 20 s iterations and then cen-
trifuged (22,000 × g) for 45 min. A 10 mL glutathione
affinity column (GE Healthcare) was prepared by washing
with ten column volumes of Buffer A (50 mM Tris·HCl,
250 mM NaCl, 10% glycerol, 2.5 mM DTT, 1 mM EDTA,
pH 8.0) containing Complete, EDTA-free Protease Inhibi-
tor cocktail. Soluble cell lysate was applied to the column
and then extensively washed with Buffer A. MK2 was
eluted from the column with Buffer A + 40 mM glutath-
ione. The GST tag was cleaved using TEV protease, typi-
cally 4–16 h at 4–15°C. The sample was then diluted ten-
fold with Buffer B (50 mM MES, 10% glycerol, pH 6.0)
and loaded onto a MonoS 10/10 column (GE Healthcare)
equilibrated with Buffer B + 20 mM NaCl. The protein was
eluted at ≈200 mM NaCl using a stepwise Buffer B/NaCl
gradient. MK2-containing fractions were pooled and con-
centrated to 10 mg/mL, and then loaded onto a Superdex
75 16/60 column (GE Healthcare) equilibrated with 50
mM Tris·HCl, 250 mM NaCl, 10% glycerol, 1 mM DTT,
pH 7.5; protein was eluted at 1 mL/min. MK2-containing
fractions were pooled and sample purity was assessed by
SDS-PAGE; protein identity was confirmed using mass
spectrometry.
Activity Assays
Enzymatic assays utilized a homogeneous time-resolved
fluorescence method (CisBio-US, Inc.) to quantitate prod-
uct formation. Reactions contained in 40 μL: varying
amounts of enzyme, 4 μM peptide substrate (Biotin-Ahx-
AKVSRSGLYRSPSMPENLNRPR), 10 μM ATP, 20 mM
MOPS, 10 mM MgCl2, 5 mM EGTA, 5 mM 2-phos-
phoglycerol, 1 mM Na3VO4, 0.01% Triton X-100, 5%
DMSO, 1 mM DTT, pH 7.2. After 60 min at room temper-
ature, reactions were quenched by adding 10 μL of 0.5 M
EDTA. Phosphorylated peptide was measured by addition
of 75 μL of 24 ng/mL Eu3+-cryptate-labeled anti-phospho-
14-3-3 binding motif (CisBio-US, Inc.), 1.47 μg/mL Sure-
Light™ allophycocyanin-streptavidin (CisBio-US, Inc.), 50
mM HEPES, 0.1% BSA, 0.01% Tween-20, 0.4 M KF. The
developed reaction was incubated in the dark at room
temperature for 10 min, then read in a time-resolved flu-
orescence detector (Perkin Elmer Discovery or BMG
Rubystar) at 620 nm and 665 nm simultaneously, using a
337 nm nitrogen laser for excitation. The 665/620 emis-
sion ratio is proportional to the amount of phosphor-
ylated peptide product. Since the HTRF method does not
provide absolute quantities of product formed, specific
activities were calculated as HTRF counts/nM MK2 pro-
tein.
Crystallization
MK2 constructs yielding more than 1 mg/L of culture were
progressed to crystallization trials. Protein was concen-
trated to 10 mg/mL using an Ultrafree-15 Biomax 10 kDa
molecular weight cut-off centrifugal filter device (Milli-
pore). Various inhibitors were added individually to con-
centrated protein stocks to a final concentration of 1 mM.
Complexed MK2 protein (0.5 μL) was mixed with 0.5 μL
of various crystallization solutions from Crystal Screen 1™
and Crystal Screen 2™ (Hampton Research) and Wizard
Screen 1™ and Wizard Screen 2™ (DeCode Biostructures).
The resulting drops were dispensed into 96-well sitting
drop trays (Greiner) using a Hydra II+1 liquid handler
(Thermo Scientific Matrix). Trays were stored at 18°C and
visualized manually. Crystallization was tested exten-
sively at 4°C, uniformly without success.
Accumulated MK2 crystallization hits suggested parame-
ters to be explored more closely in a customized robotic
screen, the most effective being the precipitating reagent
and pH range. A complete 96-well screen, designed for use
with the Hydra II+1, consisted of four 4 × 6 grid screens:
(1) (NH4)2SO4/sodium citrate, pH 7–8.5; (2) sodium
malonate, pH 7–8.5; (3) sodium phosphate; pH 7–8.5;
and (4) a randomized screen obtained by randomly mix-
ing the above three precipitants with other additives
(Table 4; see also Additional File 1 Table S8). Seven differ-
ent crystal forms were identified from this comprehensive
screen, as shown in Table 5 and Figure 4.
Crystals for inhibitor soaking were grown in sitting drops
by the vapor-diffusion method using MK2(47–366,
T222E). MK2 (1.5 μL, 10 mg/mL) was added to 1.5 μL of
reservoir solution (2 M sodium malonate, pH 5.5, and
0.01 mM Anapoe 80 [Hampton Research]) and then the
drop was sealed in vapor contact with 500 μL of reservoir
solution. Crystals grew to about 0.2 mm in size in 3 days.
For soaking, one MK2 crystal was added to 60 μL of 1 mM
inhibitor dissolved in mother liquor and incubated at
18°C overnight.
Diffraction Testing and Structure Determination
MK2/inhibitor complex crystals were harvested into a cry-
oprotectant solution (20% glycerol plus mother liquor)
using a fiber loop and flash-cooled in liquid nitrogen.BMC Structural Biology 2009, 9:16 http://www.biomedcentral.com/1472-6807/9/16
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Cystals were stored in liquid nitrogen until diffraction
testing. X-ray diffraction testing was conducted in-house
using a FR591 rotating anode generator (Bruker AXS) with
a MAR345 image plate detector (MARResearch) and
Osmic optics (Rigaku USA). A total of 535 crystals were
tested, and over 80 crystals were selected for synchrotron
data collection if diffraction reached at least 3.5-Å resolu-
tion. Advanced Photon Source (Argonne, IL) and
National Synchrotron Light Source (Upton, NY) synchro-
tron beamlines were used primarily for data collection,
although a few crystals were selected for in-house data col-
lection.
Diffraction data was processed with the HKL2000 pro-
gram suite [25]. After determining the crystal orientation,
the data were integrated with DENZO, scaled and merged
with SCALEPACK, and placed on an absolute scale and
reduced to structure factor amplitudes with TRUNCATE
[26]. Five percent of the unique reflections were assigned,
in a random fashion, to the "free" set, for calculation of
the free R-factor (Rfree) [27]; the remaining 95% of reflec-
tions constituted the "working" set, for calculation of the
R-factor (Rcryst). The x-ray diffraction data for a represent-
ative inhibitor-soaked MK2 crystal (Form IV) are summa-
rized in Table 6.
The CCP4 program suite was used to solve and refine the
structure [28]. The cross-rotation function was calculated
using MOLREP [29], using the apo MK2 structure
reported previously (Protein Data Bank entry 1KWP; [7])
as the search model. Initial coordinates were generated
based on the one solution apparent at 2.9 Å resolution.
Refinement began with rigid-body refinement in REFMAC
[30], resulting in an Rcryst of 37.0% (Rfree 40.0%) for all
reflections with |F| > 2.0σF, 20–2.9 Å. Manual rebuilding
of the model was conducted using the molecular graphics
program O [31] and examination of sigmaA-weighted
2FO-FC and FO-FC electron-density maps [32]. Restrained
refinement using REFMAC converged at an Rcryst of 22.9%
(Rfree 26.8%), 20–2.9 Å. The quality of the model was
assessed with PROCHECK [33] and WHATCHECK [34].
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